Panteleimon D Mavroudis
Overview
Explore the profile of Panteleimon D Mavroudis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
265
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Patidar K, Pillai N, Dhakal S, Avery L, Mavroudis P
Sci Rep
. 2025 Feb;
15(1):4198.
PMID: 39905178
Development of antibodies often begins with the assessment and optimization of their physicochemical properties, and their efficient engagement with the target of interest. Decisions at the early optimization stage are...
2.
Pillai N, Abos A, Teutonico D, Mavroudis P
Clin Transl Sci
. 2024 May;
17(5):e13824.
PMID: 38752574
Accurate prediction of a new compound's pharmacokinetic (PK) profile is pivotal for the success of drug discovery programs. An initial assessment of PK in preclinical species and humans is typically...
3.
Patidar K, Pillai N, Dhakal S, Avery L, Mavroudis P
J Pharmacokinet Pharmacodyn
. 2024 Feb;
51(5):477-492.
PMID: 38400996
Protein therapeutics have revolutionized the treatment of a wide range of diseases. While they have distinct physicochemical characteristics that influence their absorption, distribution, metabolism, and excretion (ADME) properties, the relationship...
4.
Mavroudis P, Pillai N, Wang Q, Pouzin C, Greene B, Fretland J
CPT Pharmacometrics Syst Pharmacol
. 2022 Aug;
11(11):1485-1496.
PMID: 36004727
Osteogenesis imperfecta (OI) is a heterogeneous group of inherited bone dysplasias characterized by reduced skeletal mass and bone fragility. Although the primary manifestation of the disease involves the skeleton, OI...
5.
Petersson C, Zhou X, Berghausen J, Cebrian D, Davies M, DeMent K, et al.
AAPS J
. 2022 Jul;
24(5):85.
PMID: 35854202
Accurate prediction of human clearance (CL) and volume of distribution at steady state (V) for small molecule drug candidates is an essential component of assessing likely efficacious dose and clinical...
6.
Pillai N, Dasgupta A, Sudsakorn S, Fretland J, Mavroudis P
Drug Discov Today
. 2022 Apr;
27(8):2209-2215.
PMID: 35364270
Machine learning (ML) approaches have been widely adopted within the early stages of the drug discovery process, particularly within the context of small-molecule drug candidates. Despite this, the use of...
7.
Acevedo A, Mavroudis P, DuBois D, Almon R, Jusko W, Androulakis I
J Pharmacokinet Pharmacodyn
. 2021 Mar;
48(3):361-374.
PMID: 33768484
A computational framework is developed to enable the characterization of genome-wide, multi-tissue circadian dynamics at the level of "functional groupings of genes" defined in the context of signaling, cellular/genetic processing...
8.
Mavroudis P, Jusko W
J Pharmacokinet Pharmacodyn
. 2021 Mar;
48(3):375-386.
PMID: 33725238
To align with daily environmental changes, most physiological processes in mammals exhibit a time-of-day rhythmicity. This circadian control of physiology is intrinsically driven by a cell-autonomous clock gene network present...
9.
Mavroudis P, Ayyar V, Jusko W
CPT Pharmacometrics Syst Pharmacol
. 2019 Jun;
8(8):557-566.
PMID: 31154668
Minimal physiologically-based pharmacokinetic (mPBPK) models are frequently used to model plasma pharmacokinetic (PK) data and utilize and yield physiologically relevant parameters. Compared with classical compartment and whole-body physiologically-based pharmacokinetic modeling...
10.
Mavroudis P, van den Anker J, Conklin L, Damsker J, Hoffman E, Nagaraju K, et al.
J Clin Pharmacol
. 2019 Feb;
59(7):979-988.
PMID: 30742306
Duchenne muscular dystrophy (DMD) is an inherited neuromuscular disorder occurring in boys and caused by mutations in the dystrophin gene. Vamorolone is a first-generation delta-9,11 compound that has favorable efficacy...